Educating Patients on Adverse Effects Related to Talquetamab in MM

Based on the trial population and end point criteria, ODAC voted for daratumumab and hyaluronidase-fijh injection for SQ use in high-risk smoldering multiple myeloma.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

A panel of experts discussed their institutions’ practices for administering bispecific antibodies, BCMA or GPRC5D, to patients with multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

CRS and ICANS occurrence were comparable for patients with relapsed/refractory multiple myeloma 75 years and older vs those younger than 75.

Investigators of the phase 1/2 CFT7455-1101 study have determined cemsidomide at a dose of 100 µg safe for expansion.